Patents by Inventor Timothy C. Scott
Timothy C. Scott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11957893Abstract: A neuromodulation therapy is delivered via at least one electrode implanted subcutaneously and superficially to a fascia layer superficial to a nerve of a patient. In one example, an implantable medical device is deployed along a superficial surface of a deep fascia tissue layer superficial to a nerve of a patient. Electrical stimulation energy is delivered to the nerve through the deep fascia tissue layer via implantable medical device electrodes.Type: GrantFiled: August 25, 2020Date of Patent: April 16, 2024Assignee: Medtronic, Inc.Inventors: Brad C. Tischendorf, John E. Kast, Thomas P. Miltich, Gordon O. Munns, Randy S. Roles, Craig L. Schmidt, Joseph J. Viavattine, Christian S. Nielsen, Prabhakar A. Tamirisa, Anthony M. Chasensky, Markus W. Reiterer, Chris J. Paidosh, Reginald D. Robinson, Bernard Q. Li, Erik R. Scott, Phillip C. Falkner, Xuan K. Wei, Eric H. Bonde, David A. Dinsmoor, Duane L. Bourget, Forrest C M Pape, Gabriela C. Molnar, Joel A. Anderson, Michael J. Ebert, Richard T. Stone, Shawn C. Kelley, Stephen J. Roddy, Timothy J. Denison, Todd V. Smith
-
Patent number: 11957894Abstract: A neuromodulation therapy is delivered via at least one electrode implanted subcutaneously and superficially to a fascia layer superficial to a nerve of a patient. In one example, an implantable medical device is deployed along a superficial surface of a deep fascia tissue layer superficial to a nerve of a patient. Electrical stimulation energy is delivered to the nerve through the deep fascia tissue layer via implantable medical device electrodes.Type: GrantFiled: August 25, 2020Date of Patent: April 16, 2024Assignee: Medtronic, Inc.Inventors: Anthony M. Chasensky, Bernard Q. Li, Brad C. Tischendorf, Chris J. Paidosh, Christian S. Nielsen, Craig L. Schmidt, David A. Dinsmoor, Duane L. Bourget, Eric H. Bonde, Erik R. Scott, Forrest C M Pape, Gabriela C. Molnar, Gordon O. Munns, Joel A. Anderson, John E. Kast, Joseph J. Viavattine, Markus W. Reiterer, Michael J. Ebert, Phillip C. Falkner, Prabhakar A. Tamirisa, Randy S. Roles, Reginald D. Robinson, Richard T. Stone, Shawn C. Kelley, Stephen J. Roddy, Thomas P. Miltich, Timothy J. Denison, Todd V. Smith, Xuan K. Wei
-
Patent number: 11945721Abstract: A hydrogen feed stream comprising oxygen and one or more impurities selected from the group consisting of nitrogen, argon, methane, carbon monoxide, carbon dioxide, and water, is purified using a cryogenic temperature swing adsorption (CTSA) process with high overall recovery of hydrogen. The CTSA is regenerated using an inert gas to prevent an explosive mixture of hydrogen and oxygen from occurring.Type: GrantFiled: February 8, 2022Date of Patent: April 2, 2024Assignee: Air Products and Chemicals, Inc.Inventors: Shubhra Jyoti Bhadra, Jeffrey R. Hufton, Timothy C. Golden, Aaron Raymond Scott, Quan Min Shao, Vishrut Garg
-
Publication number: 20240075352Abstract: A golf club head with a sole having a low stiffness compliance zone, which allows the face to deflect downward upon impact with a golf ball, is disclosed herein. The compliance zone comprises a plurality of through openings that are filled with one or more filler pieces comprising a low modulus material, all of which are located within three inches of a face section measured along a front-to-back axis of the golf club head.Type: ApplicationFiled: November 10, 2023Publication date: March 7, 2024Applicant: Topgolf Callaway Brands Corp.Inventors: Irina Ivanova, Brandon D. DeMille, Alan Hocknell, William C. Watson, Timothy G. Scott, Romulus M. Tomimbang, Justin Del Rosario
-
Patent number: 11912545Abstract: A wireless hoist system including a first hoist device having a first motor and a first wireless transceiver and a second hoist device having a second motor and a second wireless transceiver. The wireless hoist system includes a controller in wireless communication with the first wireless transceiver and the second wireless. The controller is configured to receive a user input and determine a first operation parameter and a second operation parameter based on the user input. The controller is also configured to provide, wirelessly, a first control signal indicative of the first operation parameter to the first hoist device and provide, wirelessly, a second control signal indicative of the second operation parameter to the second hoist device. The first hoist device operates based on the first control signal and the second hoist device operates based on the second control signal.Type: GrantFiled: June 26, 2020Date of Patent: February 27, 2024Assignee: Milwaukee Electric Tool CorporationInventors: Matthew Post, Gareth Mueckl, Matthew N. Thurin, Joshua D. Widder, Timothy J. Bartlett, Patrick D. Gallagher, Jarrod P. Kotes, Karly M. Schober, Kenneth W. Wolf, Terry L. Timmons, Mallory L. Marksteiner, Jonathan L. Lambert, Ryan A. Spiering, Jeremy R. Ebner, Benjamin A. Smith, James Wekwert, Brandon L. Yahr, Troy C. Thorson, Connor P. Sprague, John E. Koller, Evan M. Glanzer, John S. Scott, William F. Chapman, III, Timothy R. Obermann
-
Publication number: 20210299055Abstract: The present invention contemplates a method of treating a solid cancerous tumor in a mammalian subject by the oral administration of a solid cancerous tumor-effective amount of a halogenated xanthene (HX), the lactone thereof, a pharmaceutically acceptable salt, or a C1-C4 alkyl or aromatic ester thereof (collectively an HX compound) to that mammalian subject, and liquid and solid pharmaceutical compositions for administering the HX compound. In addition, a method of inhibiting the growth of a GI tract carcinoma of a mammalian subject by the oral administration of a solid cancerous tumor-effective amount of an HX compound, as well as solid and liquid pharmaceutical compositions therefor.Type: ApplicationFiled: March 26, 2021Publication date: September 30, 2021Applicants: Provectus Pharmatech, Inc., Governors of the University of CalgaryInventors: Eric A. WACHTER, Dominic RODRIGUES, Edward V. PERSHING, Bruce HOROWITZ, Timothy C. SCOTT, H. Craig DEES, Aru NARENDRAN
-
Patent number: 8974363Abstract: New photodynamic, topically-applicable medicaments and certain medical uses of such photodynamic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene. The halogenated xanthenes constitute a family of potent photosensitizers that become photoactivated upon illumination of the treatment site with visible wavelengths of light. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs; the mouth and digestive tract and related organs; the urinary and reproductive tracts and related organs; the respiratory tract and related organs; various other internal or external tissue surfaces, such as tissue surfaces exposed during surgery; and for treatment of a variety of conditions related to microbial or parasitic infection.Type: GrantFiled: November 8, 2007Date of Patent: March 10, 2015Assignee: Provectus Pharmatech, Inc.Inventors: H. Craig Dees, Timothy C. Scott, John Smolik, Eric A. Wachter, Walter G. Fisher
-
Patent number: 8557298Abstract: New chemotherapeutic medicaments and certain medical uses and methods for use of such chemotherapeutic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. Preferably, the halogenated xanthene is Rose Bengal or a functional derivative of Rose Bengal. The halogenated xanthenes constitute a family of useful chemotherapeutic agents that afford selective, persistent accumulation in certain tissues.Type: GrantFiled: December 6, 2007Date of Patent: October 15, 2013Assignee: Provectus Pharmatech, Inc.Inventors: Timothy C. Scott, H. Craig Dees, Eric A. Wachter
-
Patent number: 8470296Abstract: New intracorporeal radiodense medicaments and certain medical uses and methods for use of such high energy phototherapeutic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. The halogenated xanthenes constitute a family of potent radiosensitizers that become photoactivated upon irradiation of the treatment site with ionizing radiation.Type: GrantFiled: March 8, 2007Date of Patent: June 25, 2013Assignee: Provectus Pharmatech, Inc.Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Walter G. Fisher, John Smolik
-
Publication number: 20110097280Abstract: New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection.Type: ApplicationFiled: December 30, 2010Publication date: April 28, 2011Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Walter G. Fisher, John Smolik
-
Patent number: 7863047Abstract: New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection.Type: GrantFiled: April 25, 2008Date of Patent: January 4, 2011Assignee: Provectus Pharmatech, Inc.Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Walter G. Fisher, John Smolik
-
Publication number: 20100076246Abstract: New intracorporeal radiodense medicaments and certain medical uses and methods for use of such high energy phototherapeutic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. The halogenated xanthenes constitute a family of potent radiosensitizers that become photoactivated upon irradiation of the treatment site with ionizing radiation.Type: ApplicationFiled: August 19, 2009Publication date: March 25, 2010Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Walter G. Fisher, John Smolik
-
Patent number: 7648695Abstract: New chemotherapeutic medicaments and certain medical uses and methods for use of such chemotherapeutic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. Preferably, the halogenated xanthene is Rose Bengal or a functional derivative of Rose Bengal. The halogenated xanthenes constitute a family of useful chemotherapeutic agents that afford selective, persistent accumulation in certain tissues.Type: GrantFiled: July 6, 2001Date of Patent: January 19, 2010Assignee: Provectus Pharmatech, Inc.Inventors: H. Craig Dees, Timothy C. Scott
-
Publication number: 20090117199Abstract: A method for the treatment of cancer, particularly a metastatic melanoma or a neoplastic lesion, the method comprising intralesional administration of a hydrophilic vehicle comprising 4,5,6,7-Tetrachloro-2?,4?,5?,7?-tetraiodofluorescein, or a physiologically acceptable salt thereof, at a concentration of about 0.1 w/v % up to about 20 w/v % and an electrolyte comprising at least one cation selected from the group consisting of sodium, potassium, calcium and magnesium and at least one anion selected from the group consisting of chlorine, a phosphate and a nitrate, wherein the electrolyte is at a concentration of between about 0.1 w/v % and about 2 w/v % and the pH of the solution between about 4 to about 10.Type: ApplicationFiled: December 5, 2008Publication date: May 7, 2009Inventors: Timothy C. Scott, H. Craig Dees, Eric A. Wachter
-
Publication number: 20080311035Abstract: New diagnostic agents for positron emission tomography (PET) and methods for use of such agents for imaging of human or animal tissue are described, wherein a primary active component of such agents is a radiolabeled halogenated xanthene or halogenated xanthene derivative. Preferably, the radiolabeled halogenated xanthene is radiolabeled Rose Bengal or a functional derivative of Rose Bengal.Type: ApplicationFiled: August 19, 2008Publication date: December 18, 2008Inventors: Timothy C. Scott, H. Craig Dees, Eric A. Wachter
-
Patent number: 7427389Abstract: New diagnostic agents for positron emission tomography (PET) and methods for use of such agents for imaging of human or animal tissue are described, wherein a primary active component of such agents is a radiolabeled halogenated xanthene or halogenated xanthene derivative. Preferably, the radiolabeled halogenated xanthene is radiolabeled Rose Bengal or a functional derivative of Rose Bengal.Type: GrantFiled: February 3, 2005Date of Patent: September 23, 2008Assignee: Provectus Pharmatech, Inc.Inventors: Timothy C. Scott, H. Craig Dees, Eric A. Wachter
-
Publication number: 20080207746Abstract: New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection.Type: ApplicationFiled: April 25, 2008Publication date: August 28, 2008Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Walter G. Fisher, John Smolik
-
Patent number: 7402299Abstract: New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection.Type: GrantFiled: November 30, 2004Date of Patent: July 22, 2008Assignee: Provectus Pharmatech, Inc.Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Walter G. Fisher, John Smolik
-
Patent number: 7390668Abstract: New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection.Type: GrantFiled: March 6, 2001Date of Patent: June 24, 2008Assignee: Provectus Pharmatech, Inc.Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Walter G. Fisher, John Smolik
-
Publication number: 20080118578Abstract: New photodynamic, topically-applicable medicaments and certain medical uses of such photodynamic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene. The halogenated xanthenes constitute a family of potent photosensitizers that become photoactivated upon illumination of the treatment site with visible wavelengths of light. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs; the mouth and digestive tract and related organs; the urinary and reproductive tracts and related organs; the respiratory tract and related organs; various other internal or external tissue surfaces, such as tissue surfaces exposed during surgery; and for treatment of a variety of conditions related to microbial or parasitic infection.Type: ApplicationFiled: November 8, 2007Publication date: May 22, 2008Inventors: H. Craig Dees, Timothy C. Scott, John Smolik, Eric A. Wachter, Walter G. Fisher